Skip to content
Tatva Chintan Pharma logo

Tatva Chintan Pharma Chem

TATVA NSE
₹1,690.20 +53.10 (+3.24%)
P/E
62.83
View as Markdown
MCP
Close 4 Nov 2026 ₹1,690.20 +237.70 +16.4% 1Y
Start ₹1,452.50

Key Fundamentals

MicrocapChemicals & PetrochemicalsChemicals

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
7.18%
Debt to Equity
0.21
EPS (TTM)
₹26.90
Book Value
₹348.26
Market Cap
—
P/E (TTM)
62.83
P/B
4.85
ROE
5.54%
Dividend Yield
0.12%
EBITDA
₹96.70 Cr
52W High
₹2,113.60
52W Low
₹1,044.10
Day Range
₹1,611.10 – ₹1,694.00
Volume
42,156

Peer Comparison

Commodities › Chemicals › Specialty Chemicals

Tatva Chintan Pharma peer comparison
Pidilite Industries
₹1,510.2058.04₹1,54,107 Cr13.721.42%23.90%31.00%₹15,399 Cr₹2,677 Cr
Gujarat Fluorochemicals
₹4,613.3083.76₹49,073 Cr6.040.07%7.82%9.64%₹5,303 Cr₹600 Cr
Navin Fluorine International
₹8,785.0057.03₹44,060 Cr10.100.09%19.60%21.00%₹3,634 Cr₹789 Cr
Deepak Nitrite
₹1,578.4027.48₹20,919 Cr3.320.49%9.82%11.40%₹8,575 Cr₹784 Cr
Aether Industries
₹1,540.7086.90₹20,030 Cr7.880.00%9.66%11.90%₹1,231 Cr₹235 Cr
Aarti Industries
₹447.5530.57₹15,838 Cr2.590.23%7.13%6.86%₹9,010 Cr₹531 Cr
Atul
₹5,156.5019.67₹14,827 Cr2.310.59%11.50%14.90%₹6,969 Cr₹788 Cr
Tatva Chintan Pharma (this company)
₹1,690.2062.83₹3,787 Cr4.850.12%5.54%7.18%₹650 Cr₹62 Cr
Median 8 companies₹1,634.3057.54₹20,474 Cr5.450.18%9.74%11.65%₹6,136 Cr₹692 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

57 Good

Data confidence 100/100

Category scores

Quality
49
Average
Returns, margins, earnings quality 22% weight
Valuation
14
Poor
Cheap vs sector & own history 24% weight
Growth
98
Strong
Sales & profit trajectory 9% weight
Financial Health
78
Strong
Solvency, leverage, coverage 9% weight
Momentum
74
Strong
Trend strength, vol-adjusted 12% weight
Ownership
82
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is expected to give good quarter
  • Company has been maintaining a healthy dividend payout of 22.5%
  • Company's working capital requirements have reduced from 133 days to 92.0 days

Weaknesses

4
  • Stock is trading at 5.57 times its book value
  • The company has delivered a poor sales growth of 11.0% over past five years.
  • Company has a low return on equity of 3.68% over last 3 years.
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallNeutral676
OscillatorsBearish270
Moving AveragesStrong Bullish406

Key readings

RSI (14)
47.43
Neutral
MACD (12,26,9)
−35.20
Bearish
SMA (50)
1,719.84
Bearish
SMA (200)
1,407.59
Bullish

As of

Analyst Rating

Based on 2 analysts
BUY100%

2 of 2 analysts rate Buy, 0 Hold, 0 Sell.

As of

BUY
2
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
5Y+11.02%
3Y+6.07%
1Y+32.11%
TTM+49.20%

Net profit

Net profit growth by window
5Y−4.18%
3Y−2.27%
1Y+600.00%
TTM+244.44%

Operating cash flow

Operating cash flow growth by window
5Y+9.16%
3Y+3.45%
1Y+24.00%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−3.75 pp
3Y+4.19 pp
1Y+9.44 pp
TTM+6.77 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2018₹136 Cr
Mar 2019₹206 Cr
Mar 2020₹263 Cr
Mar 2021₹300 Cr
Mar 2022₹434 Cr
Mar 2023₹424 Cr
Mar 2024₹394 Cr
Mar 2025₹383 Cr
Mar 2026₹506 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2018₹12.00 Cr
Mar 2019₹21.00 Cr
Mar 2020₹38.00 Cr
Mar 2021₹52.00 Cr
Mar 2022₹96.00 Cr
Mar 2023₹45.00 Cr
Mar 2024₹30.00 Cr
Mar 2025₹6.00 Cr
Mar 2026₹42.00 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹144 Cr +49.1% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Tatva Chintan Pharma Chem trades at a market cap of ₹2,974 Cr with a PE of 69.4x and P/B of 3.74x. The company reported FY25 revenue of ₹505.86 Cr (up ~32% YoY from ₹382.71 Cr in FY24) with net profit recovering to ₹42.05 Cr from a trough of ₹5.71 Cr in FY24, though profitability remains well below its FY22 peak of ₹95.87 Cr net profit.

Bull Case 7
  • TTM revenue growth of 32% signals a strong recovery, with FY25 sales at ₹505.86 Cr vs ₹382.71 Cr in FY24
  • Net profit surged from ₹5.71 Cr in FY24 to ₹42.05 Cr in FY25, a ~636% increase indicating a cyclical earnings turnaround
  • Working capital efficiency improved significantly from 133 days to 92 days, freeing up cash flow
  • Operating profit recovered to ₹89.33 Cr in FY25 from ₹25.84 Cr in FY24, indicating margin restoration
  • Company maintains a consistent dividend payout averaging 22.5%, demonstrating shareholder return discipline
  • Stock has delivered 24% returns over the past 1 year, outperforming amid the earnings recovery
  • EPS recovered to ₹17.98 in FY25 from ₹2.44 in FY24, validating the profit turnaround trajectory
Bear Case 8
  • PE ratio of 69.4x is elevated, pricing in significant future growth that may not materialize
  • 3-year ROE averages just 4% and last year ROE is only 6%, well below cost of equity for a specialty chemicals company
  • 5-year compounded sales growth of only 11% and 5-year profit CAGR of -4% indicate a structurally weak growth record
  • Promoter holding has declined by 7.15% over last 3 years, signaling reduced insider confidence
  • FY25 net profit of ₹42.05 Cr remains 56% below the FY22 peak of ₹95.87 Cr, suggesting full recovery is still distant
  • P/B ratio of 3.74x is expensive given the low single-digit ROE profile
  • 3-year stock CAGR of -11% reflects sustained value destruction for medium-term holders
  • Dividend yield of just 0.08% offers negligible income support at current valuation

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: Recent news flow for Tatva Chintan is limited to routine corporate governance disclosures with no material positive or negative catalysts. The trading window closure signals Q1FY27 results are approaching, which will be the next meaningful data point. No operational or sector-specific headwinds have surfaced in the latest updates. Investors should watch for Q1FY27 earnings for direction on revenue trends and margin trajectory.

Neutral 2
  • Trading window closed for Q1FY27 Jun 23

    Tatva Chintan closed its trading window from July 1, 2026, until 48 hours after Q1FY27 results are declared, a routine compliance measure.

  • Investor meet with Valcore Capital Jun 12

    Tatva Chintan will hold a virtual one-on-one meeting with Valcore Capital Advisors on June 17, 2026. No unpublished price sensitive information will be shared.

Quarterly Results

₹ Cr
TATVA quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
97
84
98
105
83
86
108
117
124
131
134
167
217
Expenses
76
73
83
93
78
79
99
100
101
106
106
135
177
Operating Profit
20
11
16
13
6
7
9
17
22
25
28
32
41
OPM %
21%
13%
16%
12%
7%
8%
8%
15%
18%
19%
21%
19%
19%
Other Income
1
1
5
1
0
0
1
1
1
2
0
2.78
2
Interest
3
0
0
0
0
0
0
0
1
0
1
2
3
Depreciation
7
7
6
7
7
7
7
9
9
9
10
11
11
PBT
11
5
14
7
−1
0
2
9
14
18
17
21
29
Tax %
31%
34%
30%
24%
−34%
−165%
49%
27%
27%
14%
38%
24%
26%
Net Profit
8
3
10
5
−1
0
1
7
10
15
10
16
21
EPS (₹)
3.33
1.48
4.11
2.23
−0.28
0.06
0.44
2.84
4.24
6.49
4.41
6.83
9.17

Profit & Loss

₹ Cr
TATVA profit and loss, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
136
206
263
300
434
424
394
383
506
650
Expenses
113
172
208
234
325
363
325
348
412
523
Operating Profit
23
34
55
67
109
61
69
35
94
127
OPM %
17%
17%
21%
22%
25%
14%
17%
9%
18%
19%
Other Income
1
1
1
5
9
2
7
2
3.55
5
Interest
3
4
4
4
5
9
7
1.29
3
7
Depreciation
3
4
5
7
8
10
26
28
37
40
PBT
19
27
48
61
104
45
44
8
57
84
Tax %
35%
25%
21%
14%
8%
−2%
30%
25%
26%
—
Net Profit
12
21
38
52
96
45
30
6
42
63
EPS (₹)
6.11
10.22
18.8
26.02
43.25
20.52
12.97
2.44
17.98
26.9
Div. Payout %
0%
0%
0%
19%
5%
10%
15%
41%
11%
—

Balance Sheet

₹ Cr
TATVA balance sheet, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
8
8
8
20
22
22
23
23
23
23
Reserves
51
72
110
146
451
493
714
715
758
791
Borrowings
56
77
91
90
120
170
14
36
120
170
Other Liabilities
28
31
41
59
65
74
67
61
102
134
Total Liabilities
144
188
249
315
658
759
819
836
1,004
1,119
Fixed Assets
57
67
111
120
160
196
427
529
609
595
CWIP
10
6
5
10
51
231
77
24
25
43
Investments
1
0
0
0
0
0
10
0
4
4
Other Assets
76
115
133
185
447
332
305
283
365
477
Total Assets
144
188
249
315
658
759
819
836
1,004
1,119

Cash Flow

₹ Cr
TATVA cash flow, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
13
7
25
20
20
28
98
25
31
Investing
−30
−17
−40
−21
−197
−101
−121
−65
−116
Financing
7
17
10
−5
235
38
31
17
79
Net Cash Flow
−10
8
−5
−6
59
−36
8
−24
−6
Free Cash Flow
−18
−2
−23
−1
−69
−175
−30
−51
−82
CFO/EBITDA
105
39
61
44
36
61
157
85
42

Ratios

TATVA financial ratios, annual
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
77
73
69
110
48
73
65
85
86
Inventory Days
148
114
175
173
319
262
320
246
319
Days Payable
127
71
87
114
83
52
94
60
95
Cash Conversion Cycle
99
116
157
169
283
283
291
271
310
Working Capital Days
15
46
47
74
74
25
158
148
92
ROCE %
—
22%
28%
28%
26%
9%
7%
1%
7%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Tatva Chintan Pharma insights

65 extracted metrics across FY18–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 72.02%
  • Public 17.08%
  • FIIs 4.38%
  • Others 3.30%
  • DIIs 3.21%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: FIIs and Others. Not available separately for this quarter: the holding is recorded inside Others, so both are left blank rather than shown at a wrong split.

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Tatva Chintan Pharma Chem

What does Tatva Chintan Pharma Chem Ltd do?
Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals
Where is Tatva Chintan Pharma Chem Ltd (TATVA) listed?
Tatva Chintan Pharma Chem Ltd trades as TATVA on the NSE and under code 543321 on the BSE.
Which sector does Tatva Chintan Pharma Chem Ltd belong to?
Tatva Chintan Pharma Chem Ltd is classified under the Chemicals sector, in the Specialty Chemicals industry.
What is the PE ratio of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd trades at a PE ratio of 62.83 as of 4 Nov 2026, on earnings per share of ₹26.9, against a book value of ₹348.26 per share.
What is the 52-week high and low of Tatva Chintan Pharma Chem Ltd?
Over the last 52 weeks Tatva Chintan Pharma Chem Ltd has traded between ₹1,044.1 and ₹2,113.6 as of 4 Nov 2026.
Does Tatva Chintan Pharma Chem Ltd pay dividends?
Tatva Chintan Pharma Chem Ltd has a dividend yield of 0.12%.
What is the Return on Equity (ROE) of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd reported a return on equity of 5.54%. Its debt-to-equity ratio is 0.21.

Company Information

Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals

Website tatvachintan.com
Listed 29 Jul 2021
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/TATVA.md for Tatva Chintan Pharma Chem Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Chemical & Petrochemical stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month